Virginia Schad, PharmD

The current GWAS identified genetic variants that are associated with both short- and long-term responses to Peg IFN in patients with chronic hepatitis B.

Despite being in the age range of their mid-fifties, patients with hepatitis C who have undergone liver transplants in a time period when direct-acting antivirals are available have fared similarly to liver transplant recipients without hepatitis C.

Twins born to mothers with HCV infection had a significantly higher risk for developing inter-twin birth weight discordance.

After DAA therapy, histologic regression of liver fibrosis was shown in patients who were coinfected with hepatitis C and HIV.

Investigators of this real-world Italian study found that treatment with protease inhibitors (ie, asunaprevir/simeprevir) should be avoided in patients with advanced liver disease.

Needle and syringe programs are a highly effective, low-cost intervention to reduce HCV transmission.

Researchers found that to achieve the WHO goal for worldwide elimination of HBV, patients at risk for spontaneous HBsAg loss should be included in trials for treatments that are outside of current treatment criteria.

Treatment of HCV with grazoprevir plus elbasvir is effective in the acute phase of infection and therefore should be used in patients at high risk for HCV transmission.

Researchers found dose-related reductions in serum HBV DNA, RNA, and anti-HBV levels were achieved with the combined use of NVR 3-77 and pegIFN.

Patients with chronic HCV and renal dysfunction may be a difficult-to-treat population when considering ribavirin combination regimens.